The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2

Pu,Li; Su,Lizhong; Kang,Xixun

doi:10.3892/ijmm.2019.4193

The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2

Authors:
- Li Pu
- Lizhong Su
- Xixun Kang
View Affiliations

Affiliations: Department of Otolaryngology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China, Department of Otolaryngology, Head and Neck Surgery, Shenzhen Hospital, University of Chinese Academy of Sciences, Shenzhen, Guangdong 518106, P.R. China
Published online on: May 10, 2019 https://doi.org/10.3892/ijmm.2019.4193
Pages: 57-66
Copyright: © Pu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin is one of the primary compounds used in the treatment of nasopharyngeal carcinoma (NPC), and fibroblast growth factor receptor 2 (FGFR2) has emerged to be a promising target for treatment in various tumors. Therefore, the present study aimed to explore whether the expression levels of FGFR2 in NPC tissues and cell lines were altered, and whether the efficiency of cisplatin was increased following the downregulation of FGFR2. The downregulation of FGFR2 was achieved by transfection with a small interfering RNA against FGFR2. Tissues of patients with NPC were analyzed by immunohistochemistry. Cell viability was examined using a Cell Counting Kit‑8 assay. Cell cycle analysis was performed using flow cytometry. mRNA and protein levels were measured by reverse transcription quantitative polymerase chain reaction and western blot analysis, respectively. FGFR2 was observed to be overexpressed in cancer tissues of patients with NPC and in the NPC SUNE1, C666‑1, 6‑10B and HNE‑3 cell lines, and resulted in an unfavorable prognosis. Cisplatin treatment decreased cell viability and increased FGFR2 expression. The silencing of FGFR2 was demonstrated to augment the effects of cisplatin treatment, including decreasing the cell viability and inducing cell cycle arrest, which involved the increase and decrease of the durations of G1 and S phases, respectively, and a decrease in the expression levels of cyclin D1 and CDC25A, and increasing the rate of apoptosis via the intrinsic apoptosis pathway, as demonstrated by the upregulation of cleaved caspase‑3 and B‑cell lymphoma 2 (Bcl‑2)‑associated X protein and downregulation of Bcl‑2, in SUNE1 and C666‑1 cell lines. FGFR2 was overexpressed in the cancer tissues of patients with NPC and in NPC cell lines, resulting in an unfavorable prognosis. The downregulation of FGFR2 decreased cell viability via cell cycle arrest at G1 phase, and increased the efficacy of the cisplatin‑based induction of apoptosis through the intrinsic apoptosis pathway.

View Figures

View References

1	Liu X, Tang LL, Du XJ, Li WF, Chen L, Zhou GQ, Guo R, Liu Q, Sun Y and Ma J: Changes in disease failure risk of nasopharyngeal carcinoma over time: Analysis of 749 p atients with long-term follow-up. J Cancer. 8:455–459. 2017. View Article : Google Scholar :
2	Wilmot VV and Hathorn I: Surgical management of nasal stenosis following chemoradiation for nasopharyngeal carcinoma. J Laryngol Otol. 131:429–432. 2017. View Article : Google Scholar : PubMed/NCBI
3	Strazzulla A, Barreca GS, Giancotti A, Pisani V, Costa C, Zicca E, La Boria A, Roveda L, Liberto MC, Tucci L, et al: Nasopharyngeal carcinoma: Review of the literature with a focus on therapeutical implications. Infez Med. 23:224–229. 2015.PubMed/NCBI
4	Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M and Ornitz DM: Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 281:15694–15700. 2006. View Article : Google Scholar : PubMed/NCBI
5	Grose R and Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16:179–186. 2005. View Article : Google Scholar : PubMed/NCBI
6	Katoh M and Katoh M: FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. Int J Oncol. 22:1155–1159. 2003.PubMed/NCBI
7	Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
8	Jung EJ, Jung EJ, Min SY, Kim MA and Kim WH: Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol. 43:1559–1566. 2012. View Article : Google Scholar : PubMed/NCBI
9	Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, et al: FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 106:727–732. 2012. View Article : Google Scholar : PubMed/NCBI
10	Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG and Pollock PM: FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol. 117:125–129. 2010. View Article : Google Scholar : PubMed/NCBI
11	Riddell IA: Cisplatin and oxaliplatin: Our current understanding of their actions. Met Ions Life Sci. 18:2018.PubMed/NCBI
12	Köberle B, Tomicic MT, Usanova S and Kaina B: Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
13	Wu P, Tang Y, He J, Qi L, Jiang W and Zhao S: ARC is highly expressed in nasopharyngeal carcinoma and confers X-radiation and cisplatin resistance. Oncol Rep. 30:1807–1813. 2013. View Article : Google Scholar : PubMed/NCBI
14	Song Y, Zhou X, Bai W and Ma X: FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein. Tumour Biol. 36:4197–4202. 2015. View Article : Google Scholar : PubMed/NCBI
15	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
17	Zhang J, Upadhya D, Lu L and Reneker LW: Fibroblast growth factor receptor 2 (FGFR2) is required for corneal epithelial cell proliferation and differentiation during embryonic development. PLoS One. 10:e01170892015. View Article : Google Scholar : PubMed/NCBI
18	Zhao X, Zhou Y, Chen YU and Yu F: miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2. Oncol Lett. 11:4245–4251. 2016. View Article : Google Scholar : PubMed/NCBI
19	Williams GH and Stoeber K: The cell cycle and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar
20	Feldt M, Bjarnadottir O, Kimbung S, Jirström K, Bendahl PO, Veerla S, Grabau D, Hedenfalk I and Borgquist S: Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. J Transl Med. 13:1332015. View Article : Google Scholar : PubMed/NCBI
21	Neumann J, Boerries M, Köhler R, Giaisi M, Krammer PH, Busch H and Li-Weber M: The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints. Int J Cancer. 134:1991–2002. 2014. View Article : Google Scholar
22	Roque T, Haton C, Etienne O, Chicheportiche A, Rousseau L, Martin L, Mouthon MA and Boussin FD: Lack of a p21waf1/cip-dependent G1/S checkpoint in neural stem and progenitor cells after DNA damage in vivo. Stem Cells. 30:537–547. 2012. View Article : Google Scholar :
23	Boutros R, Lobjois V and Ducommun B: CDC 25 p hosphatases in cancer cells: Key players? Good targets? Nat Rev Cancer. 7:495–507. 2007. View Article : Google Scholar : PubMed/NCBI
24	Shen T and Huang S: The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 12:631–639. 2012. View Article : Google Scholar : PubMed/NCBI
25	Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC and Piwnica-Worms H: GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell. 13:36–47. 2008. View Article : Google Scholar : PubMed/NCBI
26	Sur S and Agrawal DK: Phosphatases and kinases regulating CDC25 activity in the cell cycle: Clinical implications of CDC25 overexpression and potential treatment strategies. Mol Cell Biochem. 416:33–46. 2016. View Article : Google Scholar : PubMed/NCBI
27	Lee KM, Santos-Ruiz L and Ferretti P: A single-point mutation in FGFR2 affects cell cycle and Tgfbeta signalling in osteoblasts. Biochim Biophys Acta. 1802:347–355. 2010. View Article : Google Scholar
28	Yin R, Bao W, Xing Y, Xi T and Gou S: MiR-19b-1 inhibits angiogenesis by blocking cell cycle progression of endothelial cells. Biochem Biophys Res Commun. 417:771–776. 2012. View Article : Google Scholar
29	Gredler ML, Seifert AW and Cohn MJ: Tissue-specific roles of Fgfr2 in development of the external genitalia. Development. 142:2203–2212. 2015. View Article : Google Scholar : PubMed/NCBI
30	Chen J, Liu S, Li Q and Peng J: Combination of cytosine arabinoside and cisplatin enhances inhibition of cell proliferation and promotes apoptosis of resistant nasopharyngeal carcinoma cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 31:379–382. 3862015.In Chinese.
31	Huang YY, Pu LJ, Song LL, Ma LY, Liu H and Jiang CC: Knockdown of GRP78 enhances cell death by cisplatin and radiotherapy in nasopharyngeal cells. Anticancer Drugs. 27:726–733. 2016. View Article : Google Scholar : PubMed/NCBI
32	Green DR and Llambi F: Cell death signaling. Cold Spring Harb Perspect Biol. 7:2015. View Article : Google Scholar : PubMed/NCBI
33	Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, Hodgkinson C, McVey R, Kitchener H and Jayson GC: Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther. 10:495–504. 2010. View Article : Google Scholar : PubMed/NCBI